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A comparison of 11C-choline PET with T2 and diffusion-
weighted MRI for delineating malignant intraprostatic lesions 





Purpose: To compare the accuracy of 11C-choline (CHOL) positron emission tomography 
(PET) with the combination of T2-weighted (T2W) and diffusion-weighted (DW) magnetic 
resonance imaging (MRI) for delineating malignant intraprostatic lesions (IPLs) for guiding 
focal therapies and to investigate factors predicting the accuracy of CHOL-PET. 
 
Methods and Materials: This study included 21 patients who underwent CHOL-PET and 
T2W-/DW-MRI prior to radical prostatectomy. Two observers manually delineated IPL 
contours for each scan, and automatic IPL contours were generated on CHOL-PET based on 
varying proportions of the maximum standardized uptake value (SUV). IPLs identified on 
prostatectomy specimens defined the reference standard contours. The imaging-based 
contours were compared with the reference standard contours using Dice similarity 
coefficient (DSC), sensitivity and specificity. Factors that could potentially predict the DSC 
of the best contouring method were analyzed using linear models. 
 
Results: The best automatic contouring method, SUV60, had similar correlations (DSC 0.59) 
with the manual PET contours (DSC 0.52, P=0.127) and significantly better correlations than 
the manual MRI contours (DSC 0.37, P<0.001). The sensitivity and specificity values were 
72% and 71% for SUV60; 53% and 86% for PET manual contouring; and 28% and 92% for 
MRI manual contouring. The tumor volume and transition zone pattern could independently 
predict the accuracy of CHOL-PET. 
 
Conclusions: CHOL-PET is superior to the combination of T2W- and DW-MRI for 
delineating IPLs. The accuracy of CHOL-PET is insufficient for gland-sparing focal therapies, 
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however may be accurate enough for focal boost therapies. The transition zone pattern is a 
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Conventional treatment modalities for localized prostate cancer such as radical prostatectomy 
and radiotherapy aim to treat the entire prostate gland, with little consideration of the location 
of the malignant intraprostatic lesion (IPL). This is despite the fact that it is uncommon for 
localized prostate cancer to involve the entire prostate. One large prostatectomy-based study 
of predominantly Gleason 7 and pT2c cases found that the tumor involved a median of only 
5% of the total prostate volume(1).  
 
Conventional whole-gland treatments pose several problems. Firstly, these treatments may 
not be necessary in lower risk patients, and may result in unnecessary treatment-related 
morbidities(2). Secondly, whole gland treatments may not treat IPLs aggressively enough in 
higher risk patients, resulting in a high likelihood of local recurrences(3-5). Focal treatments 
using modalities such as intensity-modulated radiotherapy, focal brachytherapy, focused 
ultrasound and cryotherapy have been proposed as ways of overcoming these problems(2,6-
8). Lower risk patients who need more than active surveillance may be treated by focal 
therapy to treat the IPLs only, while sparing the rest of the prostate gland(2,8,9). Higher risk 
patients may be treated by whole-gland treatment with a focal boost to IPLs to improve local 
control(9-12). These focal treatments remain investigational and have not gained widespread 
acceptance. 
 
One reason why these focal treatments have not been more widely adopted is that 
conventional imaging with modalities such as T2-weighted (T2W) MRI has not been reliable 
enough to localize IPLs(2). However, new imaging modalities such as 11C-choline (CHOL) 
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positron emission tomography (PET)(13), 11C-acetate PET(14), diffusion-weighted (DW) and 
dynamic contrast-enhanced (DCE) MRI(15), and magnetic resonance spectroscopy 
(MRS)(16,17) may more reliably identify IPLs, potentially making focal therapies a more 
viable strategy. 
 
CHOL-PET is a particularly promising imaging modality for identifying IPLs. CHOL is a 
radiotracer based on choline, an essential component of the cell membrane. Prostate cancer 
cells show changes in choline transport and choline kinase alpha expression, leading to an 
increased uptake of choline(18). However, CHOL-PET for localizing prostate cancer is 
currently controversial, with some studies showing high accuracy(13,17), whilst others show 
no advantages over T2W-MRI(16,19). 
 
The aim of this study is to compare the accuracy of CHOL-PET with T2W-MRI for 
delineating IPLs based on histopathological reference standards and to investigate factors that 
can predict the accuracy of CHOL-PET. 
 
Materials and Methods 
 
Study design and patient population 
 
This study is an analysis of data from a prospective, single institution study of 30 patients 
recruited between September 2008 and March 2011. Eligible patients included those with 
histopathologically proven prostate adenocarcinoma with intermediate to very high-risk 
factors(20), who were medically and surgically suitable for radical prostatectomy.  
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All patients had standard diagnostic and staging investigations prior to recruitment, including 
serum PSA, trans-rectal ultrasound (TRUS)-guided biopsy, whole body scintigraphic bone 
scan and CT. Following recruitment, all patients underwent pelvic MRI and pelvic CHOL-
PET/CT at least 2 weeks after the TRUS biopsy. DW-MRI was not mandated in the original 
trial protocol, but was also performed with the standard MRI sequences in 24 patients. 
Patients underwent radical prostatectomy within four weeks of the MRI and PET scans. 
Patients who did not have DW-MRI or who had significant imaging artifact that 
compromised their interpretation were excluded from the final analysis. 
 
All patients provided written informed consent, and the institutional ethics committee 
approved this study. An analysis of the same patient cohort, investigating Gleason score 




Detailed descriptions of our CHOL-PET/CT and MRI acquisition protocols have previously 
been published(13,21). CHOL-PET/CT was performed on an Allegro GSO full-ring 3D PET 
scanner (Philips Healthcare, Cleveland, OH, USA) and MRI was performed on a 3-Tesla 
Magnetom Verio system (Siemens, Erlangen, Germany) with an external body-array coil. 
MRI sequences that were analyzed in this study included multiplanar 2D T2W turbo spin-
echo (TSE) which had voxel sizes of 1.9mm x1.9mm x4.4mm, 3D T2W sampling perfection 
with application optimized contrasts using different flip angle evolutions (SPACE) which had 
voxel sizes of 1.3mm x1.3mm x1mm, and apparent diffusion coefficient maps created from 
DW-MRI which had voxel sizes of 1.2mm x1.2mm x4.4 mm. The CHOL-PET scan had 




Pathological specimen preparation 
 
The prostate was step-sectioned at 4mm transverse slices, perpendicular to its posterior 
surface, as previously described(13). The outline of the tumors was marked directly on the 
microscope slides of the prostatectomy specimens, and these slides were then scanned 
directly on a flat bed scanner.A single pathologist reviewed the specimen and outlined each 





The SPACE-MRI sequence was resampled so that the posterior surface of the prostate was 
vertical, in order to match the slice angle of the prostatectomy specimens. The DW-MRI and 
CHOL-PET scans were manually co-registered with the SPACE-MRI sequence. The 
prostatectomy specimen digital images were stacked, and reoriented to match the MRI slices. 
These images were manually deformed to match anatomical landmarks on the MRI scan as 
previously described in order to account for shrinkage and distortion of the prostate ex-
vivo(13) (Fig. 1). 
 




The deformed prostatectomy specimen digital images with IPLs marked by the pathologist 
were used to delineate the IPLs onto the primary dataset. This was used as the reference 
standard contour (Fig. 1). 
 
The index test contours consisted of MRI manual contours, CHOL-PET manual contours, and 
CHOL-PET automatic contours. Two genitourinary radiologists with minimum 12 years 
expertise (MRIobs1 and MRIobs2) independently delineated the IPLs manually using the 
combination of multiplanar TSE-, SPACE- and DW-MRI sequences (Fig. 1). Similarly, two 
nuclear medicine physicians with minimum 7 years expertise (PETobs1 and PETobs2) 
independently delineated the CHOL-PET IPLs manually. Their contours were designated 
PETobs1 and PETobs2, respectively. The CHOL-PET automatic contours were generated using 
the relative standardized uptake value (SUV) thresholding algorithms. Thresholds were set 
based on the following proportions of the SUVmax inside the prostate: 40%, 50%, 60%, 70% 
and 80%. These contours were designated SUV40, SUV50, SUV60, SUV70 and SUV80, 
respectively (Fig. 1). 
Analysis of correlation 
 
The degree of correlation was compared by the degree of voxel overlap between the different 
contours. In order to account for errors in image coregistration, a 5 mm 3D isotropic 
expansion margin was placed around each contour. Each index test contour was individually 
compared with the reference standard contours using the following metrics: Dice similarity 
coefficient (DSC), sensitivity, specificity and Youden index (YI)(13,22,23). These metrics 





The best automatic contouring method was found by determining which one had both the 
highest DSC and the highest YI. The other automatic contours were not analyzed any further. 
 
The DSC and YI values were compared between PETobsav, MRIobsav, and the best automatic 
contouring method using 2-way ANOVA (with patient and contouring method as blocking 
factors) and least significant difference (LSD) post hoc testing. 
 
Analysis of factors that may be predictive of the degree of correlation 
 
The index test contour that had the best correlation with the reference standard contour was 
investigated further to determine whether or not several patient factors could predict the 
degree of correlation as determined by DSC. The following factors were investigated: 
pathological T-stage, initial PSA, prostatectomy Gleason score, percentage pathological 
tumor volume (tumor volume as a percentage of total prostate volume), SUVmax, tumor 
configuration on prostatectomy specimen and transition zone pattern on axial T2W-MRI. We 
used the system devised by Souvatzoglou et al.(24) to classify the tumor configurations into 
four groups: (I) unifocal larger than 5 mm; (II) multifocal; (III) rind-like shaped; and (IV) 
size < 5 mm. We also developed a system for classifying the transition zone patterns on axial 
T2W-MRI into four groups: (1) homogenous low signal; (2) other pattern, not otherwise 
specified; (3) multiple well-defined high signal nodules; and (4) two round, well-defined, 
heterogeneous regions with low-signal-intensity rim (Fig. 2). Linear models were used to 
assess the effect of the factors on DSC. Each factor was first fitted independently. A model 
was then fitted that began with all factors included, and the least significant eliminated at 






Twenty-one patients of the original cohort of 30 patients were included in the final analysis 
as 6 patients did not have DW-MRIs and 3 patients had significant susceptibility 
artefactsartifacts (caused by prosthetic hips) on the DW-MRIs. The patient characteristics are 
summarized in Table 1. The mean DSC, sensitivity, specificity and YI for each contouring 
method are listed on Table 2. Of the automatic contouring methods, SUV60 had both the 
highest DSC and the highest YI with values of 0.59 and 0.43, respectively. 
 
The DSCs of SUV60, PETobsav and MRIobsav were 0.59, 0.52 and 0.37, respectively. SUV60 
was not significantly higher than PETobsav (P=0.127), however was significantly higher than 
MRIobsav (P<0.001). PETobsav was also significantly higher than MRIobsav (P<0.001). 
 
The YIs of SUV60, PETobsav and MRIobsav were 0.43, 0.39 and 0.19, respectively. SUV60 was 
not significantly higher than PETobsav (P=0.367), but it was significantly higher than MRIobsav 
(P<0.001). PETobsav was also significantly higher than MRIobsav (P=0.001). 
 
SUV60 was found to have the best DSC of all the contouring methods; therefore this method 
was investigated further to see if any patient factors may be predictive of the DSC. On 
individual comparisons, the following factors were found to be significantly correlated with 
DSC: transition zone pattern (P=0.011), tumor configuration (P=0.042), Gleason score 
(P=0.004), and percentage tumor volume (P=0.001). Transition zone pattern 4 had 
significantly lower DSCs than patterns 1 (P=0.015), 2 (P=0.004), and 3 (P=0.005). Transition 
zone patterns 1, 2 and 3 were not significantly different from each other. Tumor configuration 
IV had significantly lower DSCs than configurations I (P=0.016), II (P=0.005), and III 
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(P=0.047). Tumor configurations I, II and III were not significantly different from each other. 
There was moderate positive correlation between DSC and the Gleason score (Spearman’s 
ρ=0.567, P=0.0074). There was strong positive correlation between the DSC and the 
percentage tumor volume (Spearman’s ρ=0.665, P=0.001). 
 
On fitting linear models with all of these factors, only the transition zone pattern (P=0.006) 
and percentage tumor volume (P=0.008) remained significantly correlated with DSC. 
Patients with transition zone pattern 4 had a mean DSC of 0.35 as compared with a mean 




The main finding in this study is that both manual and automatic contouring using CHOL-
PET was superior to manual contouring using MRI for delineating the IPL when correlated 
with its histopathological reference. 
 
Automatic contouring using CHOL-PET has been assessed in two previous studies. A pilot 
study of eight patients reported SUV60 as the contouring method with the best correlation 
with histopathology(13). A similar but smaller study of four patients also reported SUV60 as 
the contouring method best correlated with histopathology(25). 
 
Several previous studies have compared CHOL-PET with MRI for localizing IPLs. 
Yamaguchi et al.(17) also found results favoring CHOL-PET as compared with MRI in their   
study of 20 patients. Other studies found that CHOL-PET was not significantly better than 
T2W-MRI(16,19). Testa et al.(16) compared CHOL-PET, T2W-MRI, and MRS in 26 
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patients. The sensitivity and specificity values were 55% and 86% for CHOL-PET, 54% and 
75% for MRI, and 81% and 67% for MRS. The best results were obtained with MRS; 
however CHOL-PET and MRI were similar. Van den Bergh et al.(19) compared CHOL-PET 
with T2W-MRI in 49 patients. They reported sensitivity and specificity values of 33.5% and 
94.6% for MRI scans and 77.4% and 44.9% for CHOL-PET scans. The sensitivity and 
specificity values of MRI found in our study were similar to Van den Bergh et al’s. The 
specificity of CHOL-PET using the SUV60 contouring method in our study was however, 
significantly higher, with sensitivity and specificity values of 75.0% and 69.7%. 
 
Our study had several significant differences in methodology that may explain the discrepant 
results with the studies described above. Firstly, all the studies described above performed 
correlations on the basis of whether or not prostate segments based on imaging matched up 
with prostate segments based on prostatectomy. The prostate segments used in the above 
studies were laterality (2 segments), sextants (6 segments) or octants at each of the apex, mid-
gland and base (24 segments). Our study performed correlations using voxels (hundreds of 
voxels per prostate volume) which is a more precise methodology(15). Secondly, the above 
studies defined PET positive lesions differently. The positive segment was defined either as 
the one with the highest SUVmax, subjectively using a nuclear medicine physician, or using 
varying SUVmax thresholds. Our study defined positive voxels using both automatic 
contouring and manual contouring using two independent observers for each scan. The fact 
that we selected the best contouring method out of a selection of methods together with more 
refined and objective voxel assessment may have resulted in our study having a better 
correlation than the previous studies. Differences in patient characteristics and image 




The second major finding in this study is that the transition zone pattern can predict for how 
well CHOL-PET can localize the IPLs. Transition zone pattern 4 is associated with poorer 
correlations than transition zone patterns 1, 2 and 3 (Fig. 2). Pattern 1 (homogeneous low 
signal) is usually associated with carcinoma arising from or invading into the transition 
zone(26,27). Pattern 2 (other pattern, not otherwise specified) is a nonspecific category. 
Pattern 3 (multiple well-defined high signal nodules) is usually associated with glandular 
benign prostatic hyperplasia(27). Pattern 4 (two round, well-defined, heterogeneous regions 
with low-signal rim) is also usually associated with benign nodular hyperplasia(26). Pattern 4 
seemed to be associated with intense CHOL-PET uptake within the transition zone, leading to 
a large false-positive volume, thus leading to poorer correlations. The main implication of 
this finding is that patients may be more appropriately selected for CHOL-PET scans by first 
performing a T2W-MRI and stratifying patients according to transition zone patterns. This 
may be helpful for guiding future clinical trials but will require prospective validation before 
routine usage.  
 
Souvatzoglou et al.(24) also performed a study to investigate factors that may predict for how 
well CHOL-PET can localize IPLs. They found that tumor configuration was the only factor 
significantly negatively influencing tumor prediction. Tumor configuration IV (size of tumor 
< 5 mm) was associated with significantly poorer correlations than the other tumor 
configurations. We also investigated Souvatzoglou et al.’s tumor configuration classification 
system in our study. On an individual comparison, tumor configuration also appeared to 
predict for the ability to localize IPLs. When all factors were fitted into the linear model 
(most notably, percentage tumor volume), tumor configuration became a non-significant 
predictor in our study. The percentage tumor volume may represent a stronger predictor for 




There are a number of limitations in this study that must be addressed. As with most imaging-
pathology correlation studies, there is uncertainty as to the accuracy of co-registration. One 
source for inaccurate co-registration is a possible discrepancy in slice angles between 
imaging and pathological specimens. We attempted to account for this by slicing the 
pathological specimens uniformly and perpendicular to the posterior surface, with 
reformatting of the imaging to be at the same slice angle for improved correlation. Another 
source of inaccurate co-registration is the fact that tissue tends to shrink and distort after 
being removed from the body. We attempted to account for this using deformable registration. 
An uncertainty expansion margin was also employed, which should compensate for some of 
the residual errors in registration. 
 
Another limitation lies in the shortcomings of the CHOL-PET scan itself. As shown by 
Souvatzoglou et al.(24), CHOL-PET cannot distinguish between benign prostatic 
hypertrophy, prostatitis and prostate cancer. Automatic contours based on the SUVmax may 
therefore be influenced by these benign pathologies. This likely plays a role in limiting the 
accuracy of SUV60. 
 
Unfortunately, the full set of multiparametric MRI sequences (including DCE-MRI and MRS) 
was not originally specified as it predated its common usage, therefore was not performed on 
all patients in this study. Several recent studies have shown multiparametric MRI to be 
sufficiently accurate to guide focal therapies(6,15), so it would be interesting to compare 





The main aim of this study was to find a strategy that can be used for guiding focal therapies 
in prostate cancer. We believe that the methodology employed in this study is appropriate to 
determine this. Unlike most previous correlation studies, correlations in our study were based 
on readily reproducible quantification of the overlapping voxels using the different 
contouring methods. This more accurately reflects the decisions that need to be made by the 
clinician delivering focal therapies. Decisions need to be made about where to target the focal 
therapy, which in many cases needs to be within the nearest few millimeters as often IPLs are 
close to dose limiting normal structures and this assessment is dependant on the imaging 
methodology used. Since the voxels used in this study are 1-4mm wide, the clinician can be 
sure that the correlation metrics used in this study are relevant to the treatment. Past studies 
which performed correlations based on large segments of the prostate (e.g. laterality, sextants, 
octants) are more relevant for issuing diagnostic imaging reports rather than guiding focal 
therapies. 
 
The question that then arises is whether or not CHOL-PET automatic contouring is accurate 
enough to guide focal therapies. For the purposes of guiding focal therapies where the rest of 
the gland is spared, CHOL-PET automatic contouring may not be sufficiently accurate. With 
a sensitivity of 72%, 28% of the true IPL volume may still lie outside of the CHOL-PET-
defined volume, and therefore may not be treated by these gland-sparing approaches. 
However, CHOL-PET may be accurate enough to guide focal boost therapy, where the whole 
gland is treated, and the IPL receives a boost of more aggressive treatment. The accuracy of 
CHOL-PET reported here is high enough such that focal boost therapy would still 
significantly increase the therapeutic ratio(9) and warrants full evaluation within the context 






CHOL-PET is superior to the combination of T2W and DW-MRI for delineating IPLs. The 
accuracy of CHOL-PET is insufficient for gland-sparing focal therapies, however may be 
accurate enough for focal boost therapies. The transition zone pattern is a new classification 
that may predict for how well CHOL-PET delineates IPLs and may be used to more 
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Figure 1. Registration and generation of contours. The T2W-MRI (a) was fused with the DW-
MRI (b) and CHOL-PET scan (c). The pathologist provided digital images of prostatectomy 
specimen axial slices (d), with the involved tumor regions colored in black. These images 
were then deformed using a mesh to match anatomical landmarks on the MRI scan, and then 
co-registered with the MRI scan (e). Contours were then created on the MRI scan (f). Four 
different contours are shown: prostate (green), radiologist-defined manual contour on MRI 
(blue), SUV60 automatic contour on CHOL-PET (yellow), and pathologist-defined tumor 
(red). Although on average, CHOL-PET contours were more accurate than MRI contours, in 





Figure 2. Transition zone patterns. Four different patterns were identified in the prostate 
transition zones on axial T2W-MRI (1a – 4a). The corresponding fused PET/MRI is shown to 
the right of these images (1b – 4b). Pattern 1 corresponds to homogeneous low signal (1a). 
Pattern 2 corresponds to another pattern, not otherwise specified (2a). Pattern 3 corresponds 
to multiple well-defined high signal nodules (3a). Pattern 4 corresponds to two round, well-
defined, heterogeneous regions with low-signal-intensity rim (4a). 
 
 
